Literature DB >> 10875429

The rationale for long-term prophylaxis of venous thromboembolism.

G Agnelli1, G B Mancini, D Biagini.   

Abstract

Prophylaxis for venous thromboembolism (VTE) after surgery has traditionally been given from the time of surgery until hospital discharge, typically ranging from 5-14 days. Recently, there has been a trend toward shorter periods of hospitalization. Furthermore, a number of prospective studies have demonstrated that a significant proportion of patients develop deep vein thrombosis (DVT) or pulmonary embolism (PE) up to 5 or 6 weeks following general or orthopedic surgery. Therefore, prolonged prophylaxis during the post-discharge period may provide clinical benefits in high-risk patients. However, the optimal duration of prophylaxis for VTE after surgery remains unclear. In elective hip replacement, four studies of prolonged prophylaxis with low-molecular-weight heparin (LMWH) for 3- 4 weeks after hospital discharge demonstrated a significant reduction in the incidence of venography-confirmed DVT. These results support the use of prolonged thromboprophylaxis in the outpatient setting. Effective outpatient prophylaxis must be safe and convenient for patients to maximize compliance and clinical benefits. Low-molecular-weight heparins are safe and effective when given at a fixed daily dose, and pharmacoeconomic studies suggest that prolonged prophylaxis with these agents may be cost-effective. Key challenges for the future include identifying the patients who require prolonged prophylaxis and determining the duration of treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10875429

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  8 in total

Review 1.  Orthogeriatric co-management for the care of older subjects with hip fracture: recommendations from an Italian intersociety consensus.

Authors:  Antonio De Vincentis; Astrid Ursula Behr; Giuseppe Bellelli; Marco Bravi; Anna Castaldo; Lucia Galluzzo; Giovanni Iolascon; Stefania Maggi; Emilio Martini; Alberto Momoli; Graziano Onder; Marco Paoletta; Luca Pietrogrande; Mauro Roselli; Mauro Ruggeri; Carmelinda Ruggiero; Fabio Santacaterina; Luigi Tritapepe; Amedeo Zurlo; Raffaele Antonelli Incalzi
Journal:  Aging Clin Exp Res       Date:  2021-07-21       Impact factor: 3.636

Review 2.  Orthopaedic surgery as a model for drug development in thrombosis.

Authors:  Ola E Dahl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Re-admission rates within 28 days of total hip replacement.

Authors:  C Cullen; D S Johnson; G Cook
Journal:  Ann R Coll Surg Engl       Date:  2006-09       Impact factor: 1.891

4.  Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.

Authors:  Ulf G Eriksson; Ulf Bredberg; Kristina Gislén; Linda C Johansson; Lars Frison; Martin Ahnoff; David Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2003-03-27       Impact factor: 2.953

Review 5.  Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.

Authors:  Sean D Sullivan; Susan R Kahn; Bruce L Davidson; Lars Borris; Patrick Bossuyt; Gary Raskob
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 6.  Prevention of venous thromboembolism in spinal surgery.

Authors:  S Brambilla; C Ruosi; G A La Maida; S Caserta
Journal:  Eur Spine J       Date:  2003-11-11       Impact factor: 3.134

7.  Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery.

Authors:  Richard J Friedman
Journal:  Thrombosis       Date:  2010-09-13

8.  Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery.

Authors:  Qiang Huang; Shu-Xing Xing; Yi Zeng; Hai-Bo Si; Zong-Ke Zhou; Bin Shen
Journal:  Orthop Surg       Date:  2019-10       Impact factor: 2.071

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.